1. Catalog
  2. Citations
  3. PubMed:25881725

PubMed: 25881725

Title
Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice.
Journal
Neuroscience
Volume
298
Issue
None
Pages
81-93
Date
2015-07-09
Authors
Babri S | Mahmoudi J | Sadigh-Eteghad S | Shanehbandi D | Talebi M

Evidence de33edab67
JSON

Moreover in Ab-received mice, treatment with PHA and Gal improved the acquisition performance on comparing with the normal saline group (p<0.001)

a(CHEBI:galanthamine) decreases act(p(MGI:App, frag("25_35"))) View Subject | View Object

Appears in Networks:

a(CHEBI:galanthamine) increases bp(GO:learning) View Subject | View Object

Appears in Networks:

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") decreases act(p(MGI:App, frag("25_35"))) View Subject | View Object

Appears in Networks:

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases bp(GO:learning) View Subject | View Object

Appears in Networks:

Evidence a8081480be
JSON

The analysis also showed significant enhancing effects of PHA and Gal on the time spent in the target quadrant on comparing with the normal saline in AD mice (p<0.001). Also, in comparison with the control group, PHA-treated AD animals did not have a significant difference (p>0.05) on the time spent in the target quadrant, but in the Gal group it was significantly lower (p<0.001) (Fig. 3).

a(CHEBI:galanthamine) increases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

Evidence e2f3eba31b
JSON

Also, no alterations in the expression of a7 nAChR mRNA were observed in pretreatment with normal saline or MLA in PHA- or Gal-treated groups (p>0.05). In the same way, the pattern of mRNA expression in the cortex (data not shown) was similar to the hippocampus (Fig. 7).

a(CHEBI:galanthamine) causesNoChange r(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") causesNoChange r(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus

a(MESH:methyllycaconitine) causesNoChange r(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus

Evidence 0b354b9a9d
JSON

The analysis also showed significant effects of PHA and Gal on the protein levels on comparing with normal saline in AD mice (p<0.001). Moreover, Gal could not completely protect the a7 nAChR protein level in AD animals. This group has a lesser a7 nAChR protein level in comparison with the control group (p<0.001) (Fig. 8). The groups showed results in the cortex similar to those observed in the hippocampus (data not shown)

a(CHEBI:galanthamine) increases p(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases p(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

Evidence 0797448e59
JSON

Inter-group analysis showed that the protein level decreased by pretreatment with selective a7 nAChR antagonist MLA (p<0.001). PHA and Gal prevent receptor destroying in AD animals, but this effect is completely abolished by MLA (p<0.001) (Fig. 9). The groups showed results in the cortex similar to those observed in the hippocampus (data not shown).

a(CHEBI:galanthamine) increases p(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases p(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

a(MESH:methyllycaconitine) decreases act(a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide")) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

a(MESH:methyllycaconitine) decreases act(a(CHEBI:galanthamine)) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

a(MESH:methyllycaconitine) decreases p(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus
MeSH
Alzheimer Disease

Evidence b6e6a325ea
JSON

Notably, PHA could completely block the Ab-impaired task acquisition and reduce escape-latency to the normal level. Furthermore, the effect of PHA against the Ab-impaired task acquisition could be abolished by the pre-treatment of the a7 nAChR antagonist MLA (p<0.001). It was also noted that blockade of a7 nAChR by MLA in the Gal-treated group resulted in a significant prolongation of the escape-latency on comparing with the Gal group (p<0.001) (Fig. 2).

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") decreases act(p(MGI:App, frag("25_35"))) View Subject | View Object

Appears in Networks:

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases bp(GO:learning) View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases act(a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide")) View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases act(a(CHEBI:galanthamine)) View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases act(p(MGI:Chrna7)) View Subject | View Object

Appears in Networks:

act(p(MGI:Chrna7)) increases bp(GO:learning) View Subject | View Object

Appears in Networks:

Evidence 7cda86b293
JSON

MLA could completely block the PHA-induced spatial memory improvement (p<0.001). Furthermore, the effect of Gal against the Ab-impaired reference memory could be abolished by the pre-treatment of the a7 nAChR antagonist MLA (p<0.001). However, a7 nAChR blockage in the Gal group has a lesser effect on reference memory in comparison of blockage of that receptor in the PHA group (p<0.05) (Fig. 4).

a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide") increases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases act(a(MESH:"N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide")) View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases act(a(CHEBI:galanthamine)) View Subject | View Object

Appears in Networks:

a(MESH:methyllycaconitine) decreases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:

Evidence 292916f9ed
JSON

Effect of a7 nAChRs blockage on time spent in target quadrant in probe trials. The implications of the a7 nAChRs on PHA- or Gal-induced spatial memory enhancement were investigated by pretreatment with normal saline or MLA. A two-way ANOVA revealed significant differences of treatment [F(1,56)=4.24, p<0.05], pretreatment [F(1,56)=96.87, p<0.001] and treatment  pretreatment interaction [F(1,32)=10.69, p<0.01]. Inter-group analysis showed that this effect was blocked by the selective a7 nAChR antagonist MLA (p<0.001).

a(MESH:methyllycaconitine) decreases act(p(MGI:Chrna7)) View Subject | View Object

Appears in Networks:

act(p(MGI:Chrna7)) increases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:

Evidence b4b1bd5894
JSON

Inter-group analysis showed that Ab increased escape latency in MWM in comparison with normal saline and sham groups (p<0.001). In addition, sham operation did not have a significant effect on escape latency in comparison with the normal saline group (p>0.05).

p(MGI:App, frag("25_35")) decreases bp(GO:learning) View Subject | View Object

Appears in Networks:

Evidence a8685ef489
JSON

Time spent in target quadrant in probe trials. On the probe trial, there was a statistically significant difference between groups as determined by a one-way ANOVA (F(4,70)=35.21, p<0.001). Post hoc analysis revealed a significant effect of Ab injection on the time spent in the target quadrant, indicating that the Ab decreased the searching time in the target quadrant on comparing with the control (p<0.001).

p(MGI:App, frag("25_35")) decreases path(MESH:"Spatial Memory") View Subject | View Object

Appears in Networks:

Evidence 6300675fa2
JSON

In contrast, brain sections of animals treated with 10-nmol-aged Ab25–35 peptide demonstrated the presence of numerous and distinct extracellular amyloid deposits, widely disseminated throughout the brain (Fig. 5).

p(MGI:App, frag("25_35")) increases a(HBP:"amyloid-beta oligomers", loc(GO:"extracellular region")) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Brain

Evidence aa25c1ad04
JSON

mRNA levels of a7 nAChR subunit. Relative quantification by using a real-time RT-PCR did not reveal any significant differences in the levels of mRNA for the a7 nAChR subunits either in the hippocampus or in the cortex of various groups (p>0.05). The groups showed results in the cortex (data not shown) similar to those observed in the hippocampus (Fig. 6).

p(MGI:App, frag("25_35")) causesNoChange r(MGI:Chrna7) View Subject | View Object

Appears in Networks:
Annotations
MeSH
Cerebral Cortex
MeSH
Hippocampus

Evidence 9813ae4e96
JSON

Post hoc analysis revealed that, levels of the a7 nAChR protein in normal saline-treated AD mice were significantly lower than its level in the control animals (p<0.001).

p(MGI:Chrna7) negativeCorrelation path(MESH:"Alzheimer Disease") View Subject | View Object

Appears in Networks:

path(MESH:"Alzheimer Disease") negativeCorrelation p(MGI:Chrna7) View Subject | View Object

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.